Rehmann Capital Advisory Group Purchases 544 Shares of Celgene Co. (CELG)
Rehmann Capital Advisory Group raised its position in Celgene Co. (NASDAQ:CELG) by 6.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,992 shares of the biopharmaceutical company’s stock after acquiring an additional 544 shares during the quarter. Rehmann Capital Advisory Group’s holdings in Celgene were worth $805,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of CELG. Ayalon Holdings Ltd. purchased a new stake in Celgene in the second quarter worth about $100,000. Atlantic Trust LLC purchased a new stake in Celgene in the second quarter worth about $101,000. Moneta Group Investment Advisors LLC increased its position in Celgene by 2,688.6% in the second quarter. Moneta Group Investment Advisors LLC now owns 10,290 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 9,921 shares in the last quarter. Harvest Fund Management Co. Ltd purchased a new stake in shares of Celgene during the third quarter worth about $132,000. Finally, City Holding Co. purchased a new stake in shares of Celgene during the second quarter worth about $143,000. 72.87% of the stock is currently owned by institutional investors.
Several analysts recently issued reports on the company. BidaskClub upgraded Celgene from a “strong sell” rating to a “sell” rating in a research report on Wednesday. Cann reiterated a “buy” rating on shares of Celgene in a research report on Monday, December 3rd. Mizuho set a $117.00 target price on Celgene and gave the stock a “buy” rating in a research report on Tuesday, October 30th. UBS Group set a $94.00 target price on Celgene and gave the stock a “buy” rating in a research report on Saturday, October 27th. Finally, Leerink Swann set a $112.00 target price on Celgene and gave the stock a “hold” rating in a research report on Friday, October 26th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $116.99.
Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.02 by $0.27. The business had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.83 billion. Celgene had a return on equity of 108.76% and a net margin of 19.64%. Research analysts expect that Celgene Co. will post 7.45 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Rehmann Capital Advisory Group Purchases 544 Shares of Celgene Co. (CELG)” was originally published by Watch List News and is owned by of Watch List News. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.watchlistnews.com/rehmann-capital-advisory-group-purchases-544-shares-of-celgene-co-celg/2670992.html.
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Further Reading: Balance Sheet
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.